The REAlease® CD3 MicroBead Kit has been developed for positive selection of CD3+ cells from PBMCs. The kit contains an indirect magnetic labeling system that allows to obtain target cells free of MicroBeads and REAlease Biotin Complex.
Related products for REAlease® CD3 MicroBead Kit, human
The REAlease® CD3 MicroBead Kit has been developed for positive selection of CD3+ cells from PBMCs. The kit contains an indirect magnetic labeling system that allows to obtain target cells free of MicroBeads and REAlease Biotin Complex.
CD3 is expressed on all T cells and CD56+ NKT cells, and is associated with the T cell receptor. Most of the human peripheral blood lymphocytes (70–80%) and thymocytes (65–85%) are CD3+. The epitope recognized by the REAlease® CD3-Biotin Complex is located on the CD3ε chain.
- Isolation of specific CD3+ cell subsets. The selected CD3+ cells can be sorted according to a second marker of interest, e.g., CD56 (NKT cells).
- Isolation of CD3+ cell subset that needs to be completely label-free.
Step-by-step REAlease MicroBeads separation procedure
Example of a separation using the REAlease® CD3 MicroBead Kit
A) CD3+ cells were isolated from human PBMCs using the REAlease® CD3 MicroBead Kit, MS Columns, and a MiniMACS™ Separator. Cells were fluorescently stained with CD3-FITC and analyzed by flow cytometry using the MACSQuant® Analyzer X. Cell debris and dead cells were excluded from the analysis based on scatter signals and propidium iodide fluorescence.
B) The efficient removal of all labels was shown by using Anti-Biotin-APC to analyze the cells by flow cytometry for the presence of REAlease Biotin Complex. Directly after isolation, the cells showed staining of biotin ("MicroBead-free CD3+ cells"), whereas the label-free CD3+ cells after the REAlease Biotin Complex release were negative for biotin similar to the non-labeled cells before separation.
Release efficiency was higher than 99% for the REAlease Anti-Biotin MicroBeads (CD3).